Diminution de la prévalence du docteur shopping de la buprénorphine entre 2004 et 2014 en France

Kernisant, Mélanie; Delorme, Jessica; Kaboré, Jean‐Luc; Brousse, Georges; Laporte, Catherine; Zénut, M.; Chenaf, Chouki; Authier, Nicolas

doi:10.1016/j.lpm.2016.10.011

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Still, the large access to treatment prescription by GPs and dispensation by community pharmacists does not mean an absence of treatment supervision, as the pharmacist has to be chosen in advance and is the only one that can deliver the drug, and that several safeguards are used to ensure the reality of the prescription. This has resulted in a low rate of doctor shopping for buprenorphine, defined as overlapping prescriptions by different physicians, estimated to be 12.6% [44]. The facilitated access to buprenorphine has been accompanied by other harm reduction measures, including syringe-exchange campaigns [45], and, more recently, the early steps of a national plan to develop take-home naloxone education programs [46,47].…”

Section: The Example Of French Health Policy Regarding Opioid Dependementioning

confidence: 99%

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine

Vorspan

Hjelmström

Simon

et al. 2019

Expert Opinion on Drug Delivery

Self Cite

View full text Add to dashboard Cite

Introduction: Since the 1990s, opioid maintenance treatments (OMTs), i.e. mostly methadone and buprenorphine, have represented the therapeutic cornerstone of opioid dependence. In France, the public health strategy on opioid dependence, identified here as the 'French model', has consisted of offering a facilitated access to buprenorphine, to reach a large treatment coverage and reduce opioidrelated mortality. Areas covered: Recently, a new formulation of subcutaneous buprenorphine depot (Buvidal®) has been approved in Europe for treatment of opioid dependence. The place of Buvidal® among the pre-existing arsenal of OMTs is discussed in the light of the pharmacological specificities of this new formulation, and with the particular standpoint of the French model on opioid dependence. Expert opinion: Buvidal® could constitute a promising treatment option mainly in case of: 1) OMT initiation, including in non-specialized addiction medicine care; 2) Discharge from prison or hospital; Diversion/misuse of 3) buprenorphine or 4) methadone; 5) Clinically stabilized patients wishing to avoid daily oral taking of the medication. As such, this new formulation should be highly accessible, which will require specific pathways through care as the product is intended to be administered by a healthcare professional.

show abstract

Section: The Example Of French Health Policy Regarding Opioid Dependementioning

confidence: 99%

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine

Vorspan

Hjelmström

Simon

et al. 2019

Expert Opinion on Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution

2019

View full text Add to dashboard Cite

Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine

Yéléhé‐Okouma

Martini²,

Lemarié³

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Opioid antagonists such as naltrexone and nalmefene are used in drug therapy for alcoholism. Nalmefene, approved in Europe in February 2013 for the reduction of alcohol consumption, is used in patients with alcohol dependence. We report 11 cases of opioid withdrawal syndrome after a single dose of nalmefene in patients usually treated with methadone, buprenorphine, but also with fentanyl or loperamide. Nalmefene is both a partial agonist and an antagonist of opioid receptors. Regarding to its opioid antagonist activity, nalmefene is contraindicated in patients with an opioid treatment. Therefore, when prescribing or delivering nalmefene, healthcare professionals need to be vigilant about any type of opioid exposure, even masked or hidden, to avoid these potential life-threatening syndromes.

show abstract

Diminution de la prévalence du docteur shopping de la buprénorphine entre 2004 et 2014 en France

Cited by 4 publications

References 26 publications

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine

Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution

Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine

Contact Info

Product

Resources

About